BioCatalystWatch
INBXWorkspace / INBX / OverviewCompany library

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. (INBX)

Price
Market cap
Next catalystExpected Q4 2026ordastobart (INBRX-106) + pembrolizumab — HexAgon-HN · Phase 2/3 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Antibody

DR5 (TRAIL receptor 2)

PreINDP1P2P3FilingApproved
Upcoming / outlook

ordastobart (INBRX-106) + pembrolizumab — HexAgon-HN

OX40 (CD134)

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

OX40 (CD134)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

INBRX-106

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

ordastobart (INBRX-106) + pembrolizumab — HexAgon-HN

OX40 (CD134)

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

Antibody

DR5 (TRAIL receptor 2)

PreINDP1P2P3FilingApproved
Upcoming / outlook

OX40 (CD134)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

OX40 (CD134)

PreINDP1P2P3FilingApproved

History / paused

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

INBX PR & News

PR & News

INBX SEC archive